In the Crosshairs: RNA Viruses OR Complement?

Nisha Asok Kumar1,2†, Umerali Kunnakkadan1,3†, Sabu Thomas4 and John Bernet Johnson1*

1 Viral Disease Biology, Department of Pathogen Biology, Rajiv Gandhi Center for Biotechnology, Thiruvananthapuram, India, 2 Manipal Academy of Higher Education, Manipal, India, 3 Department of Biotechnology, University of Kerala, Thiruvananthapuram, India, 4 Cholera and Biofilm Research Lab, Department of Pathogen Biology, Rajiv Gandhi Center for Biotechnology, Thiruvananthapuram, India

Complement, a part of the innate arm of the immune system, is integral to the frontline defense of the host against innumerable pathogens, which includes RNA viruses. Among the major groups of viruses, RNA viruses contribute significantly to the global mortality and morbidity index associated with viral infection. Despite multiple routes of entry adopted by these viruses, facing complement is inevitable. The initial interaction with complement and the nature of this interaction play an important role in determining host resistance versus susceptibility to the viral infection. Many RNA viruses are potent activators of complement, often resulting in virus neutralization. Yet, another facet of virus-induced activation is the exacerbation in pathogenesis contributing to the overall morbidity. The severity in disease and death associated with RNA virus infections shows a tip in the scale favoring viruses. Growing evidence suggest that like their DNA counterparts, RNA viruses have co-evolved to master ingenious strategies to remarkably restrict complement. Modulation of host genes involved in antiviral responses contributed prominently to the adoption of unique strategies to keep complement at bay, which included either down regulation of activation components (C3, C4) or up regulation of complement regulatory proteins. All this hints at a possible “hijacking” of the cross-talk mechanism of the host immune system. Enveloped RNA viruses have a selective advantage of not only modulating the host responses but also recruiting membrane-associated regulators of complement activation (RCAs).

This review aims to highlight the significant progress in the understanding of RNA virus–complement interactions.

Keywords: complement activation, viral evasion strategies, RNA viruses, complement regulators, virus neutralization

INTRODUCTION

The complement system (CS) is evolutionarily ancient and is a prime component of the innate immunity arsenal, capable of targeting a wide range of pathogens (1). Comprising of over 30 soluble and membrane-bound proteins, multiple functions besides anti-pathogenic activities have been attributed to the CS. Besides hepatocytes being the site of bulk synthesis of complement proteins in circulation, many other cell types including immune cells (2), adipocytes, fibroblasts, and endothelial cells also synthesize complement proteins locally as reviewed in Morgan and Gasque
(3) imparting their autocrine and paracrine functions (4). The CS operates via three pathways, namely, the classical pathway (CP), the lectin pathway (LP), and the alternative pathway (AP) (5), and functions like a cascade brought about by the sequential proteolytic cleavage of zymogens into their active fragments. Despite differences in the initial trigger, all three pathways converge at a common factor, C3, quintessential for the complement cascade to proceed. The activation of a specific pathway depends on the recognition of unique molecules associated with the pathogen. The CP is initiated by the binding of C1q to the Fc region of IgG or IgM in an antigen–antibody complex or directly to the pathogen. This leads to the autocatalytic activation of C1r, which activates the serine protease C1s, which can then sequentially cleave C4 into C4a and C4b and C2 into C2a and C2b (6). In contrast, binding of mannose binding lectin (MBL) or ficolins to unique carbohydrate moieties rich in D-mannose or L-fucose (7) on the pathogen surface [pathogen-associated molecular patterns (PAMPs)] activates the LP. This is facilitated by the activation of two MBL-associated serine proteases (MASP), MASP-1, and MASP-2 (8), leading to the cleavage of C4 and C2. Thus, C4 acts as the point where both the CP and LP merge, leading to the association of C4b and C2a, generating the C3 convertase (C4b2a; Figure 1).

The autohydrolysis of C3 to form C3(H2O) by a mechanism known as the “tick-over” helps maintain basal levels of AP. C3(H2O) thus formed further binds to factor B (FB) and factor D (FD). FD, being a serine protease, cleaves FB into Ba and Bb, resulting in the formation of C3(H2O)Bb, which, like C4b2a, cleaves C3 to form C3b and C3a. The nascent C3b formed can associate with FB and, in the presence of FD, can form C3bBb, the AP C3 convertase (9). Properdin is an important component of the AP and functions by stabilizing C3bBb and increasing its half-life by 5- to 10-fold, facilitating the further cleavage of C3 into C3b (10, 11). The C3 convertase formed by all the three pathways cleaves C3 into C3a, an anaphylatoxin, and C3b, a major opsonin. The nascent C3b is central to further amplification of the pathway and is a critical component in assembling C5 convertase of the CP/LP (C4b2a3b) and the AP (C3bBb3b), essential to cleave C5 into C5a and C5b. The C5b thus formed associates with complement components C6, C7, and C8 and multiple units of C9, resulting in the formation of a multi-protein lytic complex called the membrane-attack complex (C5b-9, MAC). Apart from the membrane lytic action of complement via the MAC, CS has a wide range of other functions. Activation products, C3a, and C5a are potent anaphylatoxins, and the opsonins C3b and C4b facilitate the engagement of innate and adaptive immune cells, playing critical roles in inducing both T- and B-cell responses (12). Active cross-talk between complement proteins and various components of the adaptive arm demonstrate the role of the CS as a connecting link between the innate and the adaptive immune system (13).

Despite the decisive roles played by the CS in host immunity, the lack in memory response and its inability to distinguish between the “self” and “non-self,” especially during unprecedented activation of complement, can be damaging to the host. This is largely checked by a highly concerted group of proteins called the regulators of complement activation (RCAs) (14). These proteins have unique domains called the complement control protein (CCP) or short consensus repeats (SCRs), composed of 60–70 amino acids with complement regulatory activities. RCAs can be either membrane-associated, e.g., CD55 (decay accelerating factor, DAF), CD46 (membrane cofactor protein, MCP), CD59, and complement receptor type I (CR1, CD35) (15), or soluble in nature, e.g., C1 inhibitor (C1INH), C4b binding protein (C4BP), and factor H (fH) (14). CD55 and CD59 are attached to the cell membrane by a glycosylphosphatidylinositol (GPI) anchor while CD46 and CD35 are transmembrane proteins. CD55 has an inherent decay accelerating activity (DAA) and mediates the rapid dissociation of the C3 and C5 convertases, while CD59 prevents MAC formation by blocking the incorporation of C9 into the cell membrane. Factor H, CD35, and CD46, on the other hand, act as cofactors for the factor I (fI)-mediated inactivation of C3b into iC3b. Among the CP specific RCAs, C1INH binds to C1r and C1s and prevents their auto activation, while C4BP acts as a cofactor for the fI-mediated inactivation of C4b into C4c and C4d. CD35 is a highly potent and multifunctional RCA, since it exhibits both decay accelerating and cofactor activities. Not only does CD35 mediate the inactivation of C3b into iC3b, but it also supports an additional cleavage of iC3b into C3c and C3dg and acts as a cofactor for the inactivation of C4b by fI.

Investigation into virus-complement interactions had garnered much interest in the past, and this interest has only grown over the years to better comprehend the nature of these interactions. The knowledge acquired has enriched our insight into not only viral pathogenesis but also the underlying mechanisms of host immunity to these pathogens. Among animal viruses, RNA viruses constitute a large group of both veterinary and clinical significance. Based on the characteristics of the genetic material, they are classified into single- or double-stranded RNA viruses of positive or negative strand polarity that is either segmented or non-segmented. Human mortality of unprecedented proportions have been brought about by RNA viruses, the well documented being the pandemic H1N1 outbreak of 1918 (Spanish flu) that killed humans in millions (16). More recent outbreaks causing widespread devastation have been attributed to RNA viruses including Ebola, Nipah, and the ongoing severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2). The nature of interaction of RNA viruses with the CS suggests a constant tussle for supremacy. This review focuses specifically on the effect of complement on RNA viruses, its role in disease severity, and the ingenious evasion strategies adopted by these viruses to counter complement.

COMPLEMENT ACTIVATION AND ITS EFFECTS ON RNA VIRUSES

RNA viruses have limited genome yet are pathogenic enough to cause devastating infections in both humans and animals. The CS that acts as a frontline defense against several pathogens is a potent barrier faced by RNA viruses (Table 1). Many characteristic features, including the molecular signatures present on the surface of RNA viruses and the presence
FIGURE 1 | Pathways of complement activation with complement regulators and inhibitors highlighted. The complement system is activated primarily through three pathways—classical pathway (CP), lectin pathway (LP), and alternative pathway (AP). The CP is activated by the recognition of antigen–antibody complexes formed on the surface of the pathogen or pathogen-infected cells by the C1 complex (C1qr2s), whereas the LP is activated by the recognition of specific carbohydrate moieties present on the surface of pathogens (PAMPs) by the MBL/ficolin–MASP 1/2 complex. Upon recognition, the complexes so formed cleave C4 and C2 into C4a and C4b and C2a and C2b, respectively. The C4b so formed binds to the membrane and associates with C2a to form the C4b2a complex, the CP/LP-C3 convertase. The C3 convertase cleaves C3 into C3a and C3b. The C3b so formed further associates with C4b2a to form the C5 convertase, C4b2a3b. AP, on the other hand, is constitutively active in the plasma by a mechanism called the “tick-over,” wherein the autohydrolysis of labile thioester bond in C3 forms C3(H2O). The latter binds to factor B and serine protease factor D. Factor D cleaves factor B into Ba and Bb and forms C3(H2O)Bb, the initial fluid-phase AP C3 convertase. It then cleaves C3 into C3a and C3b. The C3b associates further to factor B, and factor D cleaves factor B into Ba and Bb and results in the formation of surface-bound AP C3 convertase. C3bBb, stabilized by properdin. AP C3 convertase cleaves many native C3 molecules into C3a and C3b to form a positive amplification loop, with each C3b capable of forming new AP convertases. The newly formed C3b can also bind to C3bBb and forms C3bBb3b, which is the AP C5 convertase. All the pathways converge at the terminal step where the C5 convertase cleaves C5 into C5a and C5b. The C5b binds to the cell surface to which binds C6, C7, C8, and multiple molecules of C9, inserting itself into the membrane to form a multiprotein transmembrane pore called the membrane attack complex (MAC), which ultimately results in the lysis of the cell. The events in the activation cascade are regulated at various levels by a group of host proteins called the regulators of complement activation (RCAs). The regulators either can be soluble in nature (C1INH, C4BP, and FH) or are membrane-bound (CD55, CD46, CD35, and CD59). The regulatory proteins are highlighted within blue boxes. Key: CD55 (Decay accelerating factor, DAF), CD46 (Membrane cofactor protein, MCP), C1INH (C1 inhibitor), CD35 (Complement receptor 1, CR1), and FH (factor H).

or absence of envelope and neutralizing/non-neutralizing antibodies, contribute to the nature of interaction of these viruses with the CS. Even among the enveloped RNA viruses, the surface glycoproteins contribute significantly to complement activation.

Orthomyxoviruses are enveloped viruses and the two major surface proteins hemagglutinin (HA) and neuraminidase (NA) activate complement to varying degrees, with HA being the better activator (17). Normal human serum (NHS) could readily neutralize strain A/WS/1933 H1N1 influenza virus in an antibody-dependent manner, and this neutralization was dependent on C1, C3, and C4 and thereby the CP (18). Activation of AP by this strain required antibodies and properdin stabilization, resulting in the deposition of C3. Interestingly, neither AP nor the terminal pathway components aided in virus neutralization (19). In the case of influenza viruses, the glycosylation pattern of surface proteins is a critical factor determining the pathway activated and the degree of neutralization. Studies with a series of H3N2 and H1N1
| Virus family | Pathway activated | Effect of complement activation |
|-------------|-------------------|----------------------------------|
| Orthomyxoviridae | CP and AP | Ab – dependent, CP-mediated virus neutralization |
| WS/33H1N1 Influenza | CP and AP | Virus neutralization |
| Influenza A/Ibaraki/1/90 (H3N2) | CP | Ab – dependent, C-mediated neutralization |
| Influenza A/H1N1 pdm09 | CP | C-deposition followed by aggregation |
| Paramyxoviridae | CP (Ab-dependent) and AP | Resistant to neutralization |
| Nipah virus | AP | Neutralization by virolysis |
| Mumps virus | AP | Neutralization by virus aggregation |
| Parainfluenza virus 5 | AP | Lysis of infected cells |
| Parainfluenza virus 3 | CP (Ab-independent) | Virus neutralization |
| Measles virus | CP | Neutralization by virolysis |
| Newcastle disease virus (NDV) | CP, LP, and AP | Lysis of infected cells |
| Pneumoviridae | CP and AP | Ab-dependent, C-mediated, cytolysis |
| Human respiratory syncytial Virus (hRSV) | | |
| Filoviridae | LP | Neutralization |
| Ebola virus (Pseudotype) | LP | Neutralization |
| Marburg virus (Pseudotype) | | |
| Flaviviridae | LP | Neutralization |
| Hepatitis C virus | LP | Ab – dependent C-mediated Cytolysis |
| Dengue Virus | AP, CP and LP | Neutralization by virolysis, block in virus fusion |
| West Nile Virus | CP | Neutralization by virolysis |
| Zika Virus | CP | C-mediated cytolysis |
| Japanese Encephalitis Virus | CP | Neutralization |
| Togaviridae | CP (Ab-dependent) | Opsonization NOT leading to neutralization |
| Ross River virus | CP and AP (Ab – independent) | Neutralization |
| Chikungunya virus | | |
| Sindbis Virus | | |
| Rhabdoviridae | CP | Neutralization by aggregation followed by lysis |
| Vesicular Stomatitis virus | CP | Neutralization by virus aggregation following opsonization |
| Chandipura virus | CP | Neutralization by aggregation followed by lysis |
| Retroviridae | CP, LP and AP | Virolysis |

Virus families with select viruses indicating the specific pathway activated and the mechanism of neutralization. Key: CP, Classical pathway; AP, Alternative pathway; LP, Lectin pathway; C, Complement; and Ab, Antibody.

Mutants generated by swapping the HA and NA showed that those viruses with HA containing glycans rich in mannose oligosaccharides readily bound MBL and activated complement, leading to enhanced neutralization (20). The CP or LP activation by influenza viruses usually resulted in virus neutralization, which was enhanced many folds in the presence of binding antibodies (19). Direct binding of C1q to influenza B virus and the binding of MBL to the virus-infected cells facilitated active neutralization of the virus and lysis of infected cells by Guinea pig serum (17, 20). MBL could directly bind to influenza A/PR/8/34 (H3N2) and neutralize the virus and prevent the spread of virus in culture. The inhibition was due to the interaction of MBL with HA and NA (21). The complement-mediated neutralization of the PR8 strain of influenza A virus (influenza A virus A/PR/8/34) by mouse serum required the presence of natural IgM and the mechanism of neutralization was found to be the aggregation of the virus following complement deposition. The role of IgM was confirmed by using serum from Rag−/− mice (18). The role of individual pathways of complement in limiting influenza A(H1N1)pdm09 was demonstrated by the use of C3−/−, C4−/−, and FB−/− mice. Mice deficient in C3 were 100% susceptible; however, those deficient in C4 and FB were less susceptible, suggesting cross-talk between CP and AP. Simultaneous activation of both CP and AP followed by amplification through the AP enhanced the neutralization of the pandemic strain. The degree of neutralization correlated with the degree of C3b deposition and other complement components generated. Significant deposition of C3b observed on the surface of the seasonal influenza A (H3N2) compared to the pandemic virus suggest the preference of C3b for certain carbohydrates and its specificity to certain binding sites on them. The alteration in the C3b acceptor site on the surface glycoproteins, HA, and NA on the pandemic virus requires IgG to mediate the binding of C3b on them. Antagonists of C3a and C5a, and the corresponding receptor knock-out mice, showed that C5a played a less significant role in limiting the influenza A(H1N1)pdm09 virus infection (22).

Paramyxoviruses are negative-sense, single-stranded RNA viruses known to cause a number of important human diseases.
including mumps, measles, and the deadly Nipah encephalitis. Nipah (NiV) and Hendra (HeV) viruses belonging to the genus *Henipavirus* of the *Paramyxoviridae* family are deadly BSL4 pathogens. Nipah virus has two major glycoproteins, the fusion protein (F), and the glycoprotein (G). Using VSV-based pseudoviruses expressing F and G glycoproteins, it was demonstrated that these glycoproteins activate the AP. However, when the pseudotypes were primed with specific antibodies, and more interestingly with the soluble EphrinB2 (the cognate receptor for NiV) linked to the Fc region of human IgG1, the CP was found to be predominantly activated (23). Among other paramyxoviruses, parainfluenza virus 5 (PIV5), and mumps virus (MuV) were found to activate the AP, while parainfluenza virus 3 (PIV3) activated CP independent of antibodies (24–28). Natural antibodies present in the NHS was found to bind to PIV5, yet CP was not activated; however, a dramatic switch from AP to CP was noticed when a single amino acid change, G3A, was engineered in the F protein (29). This clearly suggests the importance of surface glycoproteins in determining the pathway activated. Besides complement activation, the interaction of surface glycoproteins with complement proteins is critical in determining the mechanism of neutralization. The overall structure and conformation of the viral proteins and more specifically key epitopes are important factors determining the sensitivity of the virus to specific complement pathways. Although the closely related PIV5 and MuV both activated the AP, the mechanism of neutralization is quite distinct; while PIV5 aggregated in the presence of complement, significant lysis was observed in the case of MuV (27). Newcastle disease virus (NDV), an avian paramyxovirus, was found to activate complement and the neutralization was dependent on all the three pathways. C3, C4, and C5 were found to be critical components for virus neutralization (30). Apart from the importance of the complement components, the cells in which the virus is cultured and the complement source also dictated the extent of neutralization. Egg-grown NDV was readily neutralized by human complement while primate cell derived NDV resisted neutralization (30, 31). Measles virus was found to be a potent activator of the AP, where the fusion protein (F) and not the hemagglutinin protein (HA) contributed significantly toward this activation (25). Measles virus-infected cells sensitized with antibodies against the F and HA, when exposed to C4-deficient serum, were lysed, suggesting a role for the AP (26). An antibody-independent activation of AP by measles virus-infected cells has also been reported (32). Human respiratory syncytial virus (hRSV) is an enveloped virus and a member of the family *Pneumoviridae* known to cause respiratory infections in children. Deposition of antibodies IgG, IgA, IgM, and IgE bound to hRSV antigens in the nasopharyngeal cells of children with acute hRSV infection suggested a role of complement activation in hRSV infection (33). An antibody-dependent protection in hRSV infection was later confirmed in complement-deficient mice (34, 35). HeLa cells infected with hRSV activated both CP and AP; however, anti-hRSV antibodies were required for cytolysis by complement (36, 37). The importance of pulmonary macrophages and the CS in restricting hRSV replication suggests the significance of local complement production in limiting RNA viruses (34).

Flaviviruses are a family of positive-sense, single-stranded RNA viruses primarily transmitted by ticks and mosquitoes with notable exception like the hepatitis C virus (HCV). This family of viruses is distributed globally and can cause a wide range of human illnesses including dengue hemorrhagic fever (DHF), yellow fever, and West Nile encephalitis. The LP plays a critical role in the neutralization of HCV, wherein MBL binds directly to the E1 and E2 surface glycoprotein and activate LP by engaging MASP-2 (38). The NS1 protein of dengue virus (DENV) plays an important role in complement activation. It is secreted by the infected cells and accumulates in the serum of the infected patients and can also bind back to the infected cells. The NS1 protein of dengue virus can activate complement in an antibody-independent manner; however, engagement of anti-NS1 antibody with cell surface-bound NS1 further accentuates complement activation leading to cytolysis (39–41). A key feature in DENV pathogenesis is antibody-dependent enhancement (ADE) of infectivity. Low-avidity antibodies arising from a prior exposure to a specific DENV can cross-react with other DENV serotypes during a subsequent infection, resulting in ADE and disease severity. The binding of C1q to human anti-*flavivirus* antibodies results in marked reduction of ADE in an IgG subclass-dependent manner (42, 43). Among the pool of antibodies against Japanese encephalitis virus (JEV) surface proteins in the convalescent sera of patients in JEV endemic areas, only anti-NS1 antibodies supported complement-dependent cytolysis of infected cells (44). West Nile virus (WNV) transmitted mainly through the bites of infected mosquitoes can cause fatal neurological disease in humans. The role of complement in restricting WNV infectivity was also demonstrated in vivo. Compared to wtC57BL6 mice, C3−/−, CR1−/−, and CR2−/− mice were highly susceptible to WNV infection. Virus neutralization by complement was much enhanced in the presence of an antibody against the envelope protein (E) of WNV (45). The neutralization of WNV by serum complement was antibody dependent nevertheless; MBL was also found to directly bind to the virus, promoting opsonization by complement components and limiting virus entry (45, 46). While binding of C1q directly to the E protein of DENV could reduce virus infectivity, it was found to enhance the WNV neutralization potential of anti-WNV antibodies even at a low antibody titer (47–49). Recognition of N-linked glycans on the surface proteins of both WNV and DENV by MBL activated the LP, resulting in virus neutralization by blocking virus fusion (50, 51). Interestingly, components of all three complement pathways are essential for limiting the WNV infection (45, 50, 52). Using factor B−/−, factor D−/−, C1q−/−, and C4−/− mice, it was clearly demonstrated that deficiency in AP components contributed significantly to neuropathogenesis, while deficiency in CP/LP components drastically affected the adaptive responses required to restrict WNV infection (52). While the neutralization of WNV and DENV by complement showed marked dependency on MBL, a less important role for the terminal pathway complement components including C5 was observed in the case of WNV (51, 53). Among the flaviviruses, the interaction of E protein–antibody complex with complement components plays a
critical role in the reduction of infectivity. Neutralization of Zika virus (ZIKV), another mosquito-borne flavivirus, associated with microcephaly in the neonates and Guillain–Barré syndrome in the adults was largely dependent on CP. Natural IgM antibodies were found to have a protective role against ZIKV. The binding of C1q to both envelope (E) and NS1 proteins followed by MAC formation resulted in virolysis (54).

The Togaviridae is a family of enveloped, positive-sense single-stranded RNA viruses distributed globally. This family consists of two genera, namely, Alphavirus, and Rubivirus. Extensive studies on Sindbis virus of the Alphavirus genus showed that while the virus was capable of activating both the AP and CP, the degree of activation of AP depended on the levels of sialic acid, with low levels being a better activator of AP (55, 56). Other alphaviruses investigated for their interactions with the CS include the Ross River virus (RRV) and Chikungunya virus (CHIKV), wherein the role of complement was rather destructive to the host than protective during virus infection. CHIKV was also found to activate complement, resulting in the deposition of complement components C3b and C4b on the surface of the virus (57).

Rhabdoviruses are negative-sense, single-stranded RNA viruses with broad tropism ranging from plants to mammals. Members of the vesiculovirus, lyssavirus, and ephemervirus genera of the Rhabdoviridae family are known to cause infection in mammals. Vesicular stomatitis virus (VSV), a prototypic member of the genus vesiculovirus, was found to activate the CP of complement either in an antibody-dependent or independent manner. Natural IgM present in the serum was found to enhance the complement-mediated neutralization by opsonization (58, 59). Activation of complement by VSV results in initial aggregation of the virus followed by virolysis (60). Chandipura virus (CHPV), another vesiculovirus and a potent human pathogen, has also been shown to activate the CP, which involved the direct binding of C1q to the virus. This virus was highly sensitive to complement and was neutralized effectively by complement-dependent virus aggregation (61). Although VSV and CHPV belong to the same genus with a single glycoprotein (G) in the virus envelope, marked differences were observed in the mechanism of neutralization. This suggests that the interaction of viruses even within the same genus can be quite complex, thus requiring extensive investigation. Filoviruses are negative-sense, single-stranded RNA viruses with characteristic filamentous virus particles. This family of viruses includes the highly pathogenic Marburg and Ebola (EBOV) viruses known to cause fatal hemorrhagic fever. The EBOV and Marburg virus glycoproteins were found to activate the LP; however, the binding of MBL to EBOV had a mixed effect of either promoting LP progression or promoting virus entry (62).

Human immunodeficiency virus (HIV), an enveloped retrovirus, is known to activate the CP and LP independent of antibody, with direct binding of C1q to gp41 acting as a trigger for CP activation (63–66). Interaction of gp120 of HIV with the components of the CP, LP, and AP further induces complement activation. Interestingly, the CP was activated by HIV in the sera of rabbit, mouse, and guinea pig, resulting in the lysis of both virus and virus-infected cells (67–69). Enhanced activation of CP by antibodies against HIV followed by opsonization with C3 occurs during seroconversion and after transition to chronic phase (70). Human T-cell leukemia virus type 1 (HTLV-1) binds directly to C1q via its extramembrane region of the envelope protein gp21. However, binding of C1q to the cell-free virion not only inhibited its potency to infect cells but also resisted lysis by human serum. Treatment with anti C1q antibody could, however, reverse the inhibitory effect (71).

As discussed above, complement activation by many RNA viruses results in their neutralization; however, there have been exceptions to this rule. In the case of NiV, the presence of the F and G glycoproteins was sufficient to protect the VSV pseudotypes from being neutralized by complement (23). This resistance was further confirmed with wild-type NiV, which, upon exposure to complement, was found to be completely resistant to neutralization with marked reduction in surface deposition of C3b in comparison to PIV5 (72). Interestingly, similar observations were made during our investigations with CHIKV, wherein the virus was found to resist complement-mediated neutralization. Complement activation by CHIKV did result in deposition of C3b and C4b on the virus, but to a lesser degree (57). The inherent resistance of complement observed in the case of both CHIKV and NiV alludes to a virus-associated mechanism for complement resistance discussed in much detail later. Earlier in vitro studies demonstrated that RRV could not independently activate the AP or CP (73). However, the role of C3 in RRV pathogenesis was established when it was observed that the disease associated with RRV infection was severe in wtC57BL6 mice compared to C3−/− mice (74). Extensive studies had shown that the binding of MBL to the glycans associated with the E2 glycoprotein on the RRV-infected cells enhanced the disease severity in the host (75, 76).

The outbreak of the novel SARS-CoV-2 has had a devastating effect globally. Human coronaviruses belong to the family Coronaviridae and primarily affect the respiratory and gastrointestinal tract of a range of animals including mammals and birds. Clinical studies based on the 2003 SARS-CoV outbreak have highlighted the significance of LP in limiting the infection. The direct binding of the spike protein (S) of SARS-CoV to the carbohydrate recognition domain of MBL resulted in complement activation and C4 deposition on virus-infected cells. The residue on the S protein that binds to MBL was identified as the N-linked glycosylation at N330 (77). This residue is close to the angiotensin-converting enzyme 2 (ACE-2) receptor binding site on the virus. The MBL-S protein interaction did not affect SARS-CoV binding to ACE-2 but blocked the binding of the virus to C-type lectin (DC-SIGN) (78). Therefore, a direct correlation of MBL versus susceptibility to virus could be drawn as most patients with SARS had MBL levels in serum significantly lower than the controls. Proteomic analysis of serum proteins from SARS patients showed significantly higher levels of C3c compared to the control sera, suggesting complement activation during SARS-CoV infection (79). Further, the N protein of SARS-CoV2 was found to activate MASP-2, leading to the aberrant complement activation and deposition of MASP-2 and C4 in the lung tissue of severely affected COVID-19 patients (80). In another study, extensive deposition of C5b-9, C4d, and MASP-2 was observed in the postmortem lungs of COVID-19 patients.
Interestingly, the severity of RRV-induced symptoms in C1q-correlated with the enhanced disease severity in the former. The role of complement in the severity of DENV disease include the observed (87, 90–92). Other key observations supporting a role and reduction in complement components in the plasma of supported by the findings that prior to enhanced consumption contributing directly to DSS (52, 84–89). This is further (DSS), complement activation caused significant damage to the tissue of RRV infected wtC57BL6 compared to MBL−/− mouse, despite marked similarities in the level of immune cell infiltration. This clearly demonstrated the importance of C3 in promoting disease rather than limiting the virus spread (74). Further studies demonstrated that the severity in the arthritic disease is dependent on complement receptor 3 (CR3 or CD11b/CD18). CR3−/− mice had only mild disease symptoms; however, similar to the C3−/− mice, the absence of CR3 did not affect recruitment of cellular infiltrate at the localized sites of inflammation. Therefore, the CR3-dependent signaling that is required for the overall expression of proinflammatory molecules was found to be the contributing factor for disease severity (83). In addition to C3, MBL and hence the LP contributed to the disease severity in mouse models of RRV infection, as increased deposition of MBL in the muscle tissue of RRV infected wtC57BL6 compared to MBL−/− mouse correlated with the enhanced disease severity in the former. Interestingly, the severity of RRV-induced symptoms in C1q−/− and Factor B−/− mice were comparable to wild type, suggesting the decisive role of LP in the disease prognosis. The glycans on the E2 protein of RRV was found to be the recognition sites for MBL, as mice infected with mutant RRV lacking the glycans had less pronounced symptoms despite both the viral load and the infiltration of proinflammatory cells being comparable to mice infected with wild-type RRV (75). These findings are clinically relevant as it was also demonstrated in the same study that human patients with RRV infections had substantially higher concentrations of MBL in both serum and synovial fluids compared to that of healthy individuals (75). Hence, it is clear that complement contributes significantly to the overall disease severity during RRV infection.

The role of complement in disease enhancement has also been well documented in flaviviral infection. In severe forms of DENV infection including DHF and dengue shock syndrome (DSS), complement activation caused significant damage to the host. Complement activation markers C3a and C5a (potent anaphylatoxins) were found to promote vascular leakage, contributing directly to DSS (52, 84–89). This is further supported by the findings that prior to enhanced consumption and reduction in complement components in the plasma of DSS patients, a significant increase in C3a and C5a was observed (87, 90–92). Other key observations supporting a role for complement in the severity of DENV disease include the activation of complement followed by MAC formation in the presence of anti-DENV antibodies; enhanced levels of C5a, C3a, and protein involved HIV-1 co-receptor engagement by both laboratory and primary isolates of HIV-1. Most importantly, the C3 induced was biologically active in the complement cascade (100). These findings hold huge significance as elevated levels of C3 and C4 in the CSF of HIV-infected individuals have been reported (101). In addition to this, significant up regulation in the cerebral synthesis of complement factors, C1q and C3, was observed in a range of cell types including astrocytes, neurons, microglia, infiltrating macrophages, and multinuclear giant cells in monkeys challenged with simian immunodeficiency virus (SIV) compared to the control animals. Up regulation also led to the enhanced deposition of both C3 and C1q on neighboring neuronal cells leading to lysis (102). This could possibly account for the cellular damage in brain
observed during neuro-AIDS. Peripheral blood T-lymphocytes from HIV-infected patients had decreased levels of CD59, suggesting suppression of CD59 expression by HIV (103). Upon exposure of human neuronal (SK-N-SH) and astrocyte (T98G) cell lines to either recombinant HIV gp41 protein or an immunodominant gp41 peptide, significant reduction in CD59 mRNA and protein was observed (104). These findings further substantiate that not only CD59 but also other proteins of the complement activation pathway are modulated by HIV. This, in turn, may contribute to the neuronal and glial cell damage in HAND patients.

Persistent activation of complement is one of the causative factors in chronic HCV infections, which may further lead to liver fibrosis (105). Contribution of C5 in mediating HCV-associated hepatic fibrosis was elucidated in vivo, and treatment with small-molecule inhibitors against C5aR exhibited antifibrotic effects (105). Several experimental and clinical studies so far support the involvement of complement dysregulation in intra- and extrahepatic disorders like type II mixed cryoglobulinemia (MC) and B cell lymphoma (106). A higher prevalence of anti-C1q antibodies among HCV genotype IV-infected patients with extrahepatic autoimmune involvement has been reported. HCV patients with immune complex diseases like systemic lupus erythematosus, cryoglobulinemia, glomerulonephritis, vasculitis, and severe rheumatoid arthritis had significantly higher levels of anti-C1q antibodies, which correlated to decreased C4 levels (107, 108). Hence, sustained activation of complement or suppression of complement by the core protein of HCV added to the significantly high levels of anti-C1q antibodies support manifestation of HCV-associated liver diseases.

More recently, MASP-2 has been implicated as one of the factors contributing to aggravated lung injury in COVID-19 pathogenesis. It was demonstrated that the N-protein, a secreted protein of SARS-CoV, MERS-CoV, and SARS-CoV-2, binds to MASP-2 (80). The binding site for MASP-2 on the N-protein of SARS-CoV was identified to be between the amino acid residues 116–124 in the coil motif of the N-protein. Binding of MASP-2 to the N-proteins of SARS-CoV-2 and MERS-CoV was traced to N (115–123) and N (104–112) regions that shared a high level of identity with the SARS-CoV N (116–124) motif. The N-proteins of all three viruses potentiated MBL–MASP-2 interaction, resulting in aberrant complement activation and subsequent deposition of C3 and C4 component. Using an adenovirus system encoding SARS-CoV-N and MERS-CoV-N, the investigators could further substantiate the role of N protein in acute inflammation. Administration of CIINH or an antibody against MASP-2 could substantially limit the damage. These findings were further validated using MASP-2 knockout mice, wherein the disease symptoms post N-protein challenge were less severe with longer survival rates than that of the wild-type mice, suggesting the importance of MASP-2 in SARS infection (80). The immunohistochemical analysis of postmortem lung tissues from five COVID-19 patients who died of respiratory failure showed enhanced deposition of MBL, MASP-2, and other markers including C4d and C5b-9 co-localizing with S protein of SARS-CoV-2 (80, 81). The serum samples also had elevated levels of C5a, suggesting hyperactivation of complement systemically or as a result of leakage of activated fragments from diseased lung (82). SARS-CoV-2-infected A549 cells showed differential expression of C3, C1r, and other complement proteins. Serum C3 levels were reduced in ∼57% of individuals, suggesting C3 consumption followed by complement activation (109). Of much interest was the finding that the anti-C5a antibody (BDB-001) had much promise in the recovery of severe COVID-19 patients (80, 82). Thus, the overall effect of RNA virus-complement interaction can be multifaceted as these interactions can either limit or promote the severity of disease.

**COMPLEMENT AT THE CROSSROADS OF INNATE AND ADAPTIVE IMMUNITY IN RNA VIRUS INFECTION**

A growing body of investigation reveals that the delicate balance between complement activation and regulation is one focal point of the disease outcome in viral infections. Apart from the immense role it plays in innate immunity, ample evidence points to the existence of cross-talk between the CS and the adaptive immune system.

Increased levels of C3a and C5a in the bronchoalveolar lavage fluid (BALF) and serum from patients infected with H1N1 pandemic virus suggest their role in virus-induced acute lung injury (ALI). The increased expression of C5aR on dendritic cells (DCs) promoted CD8⁺ T cell activation by C5a. Mice treated with C5aR-specific antagonist showed a reduction in the flu virus-specific CD8⁺ T cells accompanied by attenuated cytolysis in the lung (110). C5a-mediated leucopenia, reduced antigen-presenting cells, and impaired T cell responses had been observed in severe H7N9 influenza infection (111, 112). C5a being a chemoattractant for neutrophils and monocytes activates these cells to generate reactive oxygen species (ROS) (113). Studies from mice infected with influenza suggested a critical role of ROS in infection-induced pneumonia (114). Treatment with antioxidants could effectively reduce the lung damage and mortality in these mice (115). Increased expression of C5aR1 in bronchial epithelial and inflammatory cells accompanied by increase in C5a levels and deposition of C3 and C5b-9 in patients points to the association of C5a-C5R1 signaling in the systemic inflammatory response and the local tissue damage. Blockade of C5aR1 restricted viral replication in lung tissue and also alleviated ALI (116). The C3d and C3a generated during influenza A(H1N1)pdm09 infection plays a crucial role in evoking B cell as well as CD4⁺ and CD8⁺ T cell responses, which helps to contain the virus infection (22). The role of MBL in up-regulating inflammatory responses causing tissue damage was demonstrated in MBL knockout (KO) mice challenged with the pandemic H1N1 or the avian influenza H9N2/G1. The KO mice developed less severe disease as indicated by the reduced weight loss when compared to the wild type. Increased levels of proinflammatory cytokines and chemokines in the wild-type mice were also observed when compared to MBL KO mice.
suggesting a role of MBL as a contributing factor to disease severity (117).

Increased viral load in the brain of mice infected with WNV, in the absence of C3 or CR1/CR2, suggested their importance in limiting viral infection. Deficiency in the components of the CP (C4 and C1q) was associated with decreased splenic infections and impaired B and T cell responses to WNV infection as C4 generated anti-WNV IgM responses, while C4 and C1q were required for anti-WNV IgG responses (45). In mouse macrophages, a CR3 mediated complement-dependent enhancement of WNV infection was observed.

Hepatitis C virus is known to cause persistent infections in individuals which later on may lead to chronic liver diseases such as cirrhosis and hepatocellular carcinoma. Defective expansion and differentiation of HCV-specific T cells observed in chronic HCV patients suggest an impaired antiviral immune response during the early stages of infection. A role of HIV core protein in immunomodulatory functions was demonstrated in chronic HCV patients and in vivo (118). The interaction of HCV core protein with gC1q receptor on human monocytederived DCs inhibited TLR-induced IL-12 production alone and not any other cytokines induced by TLR (119). Moreover, the engagement of core protein with gC1qR on the DCs also inhibited the production of IL-12 and mediated the production of Th2-induced cytokines such as IL-4 upon co-culturing with CD4+ T cells. Patients with chronic HCV infection showed persistent expression of gC1qR+ CD4+ T cells, impairing T cell responses (120). These results taken together suggest that HCV limits the induction of Th1 response through the binding of core protein to gC1qR on the DCs, contributing to viral persistence (119).

The binding of HIV-1 gp41 to gC1qR on uninfected CD4+ T lymphocytes resulted in NK cell-mediated lysis of these cells during HIV infection (121). HIV, during its dissemination through the bloodstream, is opsonized and adheres to the erythrocyte membrane through CR1. The presence of antibodies enhances this binding (122). The absence of complement opsonins on HIV or the blockade of CR1 inhibited virus adherence to RBCs. The CR1 inactivates C3b into iC3b and C3d. The C3d-bound HIV-1 is then trapped in follicular dendritic cells (FDCs), where it remains infectious and intact, acting as a reservoir (123). Opsonized HIV can also bind to B cells expressing CR-2 and further results in B-cell-mediated transmission of the virion to HIV-negative CD4+ T cells in a CR1- or CR2-dependent manner (124). CR3 also plays an important role in HIV infection via modulating TLR 8-mediated signal transduction (125). Ospozonization of retroviral particles with complement proteins has been shown to enhance the ability of DCs to induce the activation, expansion, and differentiation of virus-specific cytotoxic T lymphocyte (CTL) responses, both in vitro and in vivo (126). Exposure of DCs to C-opsonized HIV was able to activate DCs, which, in turn, stimulated CTLs to elicit antiviral activity, significantly better than non-opsonized HIV (126). The presence of HIV-specific CTLs correlated with the decline in viremia during the acute phase, but not during the chronic phase of infection (127, 128). The susceptibility of monocyte-derived macrophages (MDM) to HIV-1 infection was enhanced multiple folds upon pre-exposure to C5a or C5a desArg8. This was attributed to a notable increase in the secretion of TNF-α and IL-6, suggesting the role of complement anaphylatoxin in inducing proinflammatory responses, thereby supporting virus infection (129). Thus, C5a-elicted proinflammatory cytokines and recruited DCs can indirectly promote infection of MDMs and T cells (129, 130). HIV-complement interaction results in the generation of C5a, which, besides its anaphylactic property, can exert its function by interacting with C5a receptor 1 (C5aR1; CD88) and C5a receptor 2 (C5αR2, C5L2). In myeloid cells, C5aR1 heterodimerization with CCR5, a co-receptor for HIV, was observed. C5a receptor-specific antagonist or neutralizing monoclonal antibodies against C5αR1 could limit the integration of the R5 strain of HIV in MDM by reducing the CCR5 expression. Since the levels of C5αR1 in MDM of CCR5D32 homozygous individuals were comparable to that of the normal controls, it is evident that C5αR1 works in concert with CCR5 promoting HIV entry into macrophages (131). The opsonization of HIV-1 by complement is a critical factor in driving the hyper-expression and secretion of key cytokines, transforming growth factor β (TGF β), interleukin 1b (IL-1b), interleukin 6 (IL-6), and interleukin 23 (IL-23) in DCs supporting the T helper 17 cell (TH17) induction. The opsonized HIV mediated the expression of TH17 polarizing cytokines in DCs, via the extracellular signal-related kinases (ERK) and induced C3α production in these DCs, enhancing TH17 polarization (132). The type of opsonin on HIV also determined the type of response generated in DCs. While exposure of DCs to complement-opsonized HIV supported HIV-specific CD8+ T cell response, HIV opsonized with IgG dampened this response (133). DCs are known to mount potent antiviral responses that can limit HIV infection, which includes the Sterile alpha motif and HD-domain-containing protein 1 (SAMHD1)-mediated response. However, complement-opsonized HIV overcomes SAMHD1 and other restrictions mounted by DCs to productively infect these cells. Interestingly, the degradation of SAMHD1 was not observed but phosphorylation of Tσ92 in SAMHD1 restricted intracellular replication of HIV-1. Not only was the virus replication restricted, complement-opsonized HIV induced multiple changes in the DCs including DC maturation and expression of co-stimulatory molecules of Type I interferon genes, thereby stimulating HIV-specific CD4+ and CD8+ cells (134).

The disease progression to severe pneumonia and acute respiratory distress in SARS patients has been attributed to the hyperactivation of complement (135). The systemic activation of complement mediated by MBL in SARS-CoV-2 has also been demonstrated by the co-localization of MASp2 with the spike protein (S) in the lungs of COVID-19 patients (81). Most of the disease-associated inflammation and hypercoagulability is a direct effect of the binding of the complement component C5a to its receptor, C5αR on the T cells, activating them. This binding results in a hyper-inflammatory response called the “cytokine storm” (136). C5a also promotes immune paresis and exhaustion of antigen-specific lymphocytes in cases of higher viral load. C5α-mediated IL-6 and IL-8 release in SARS-CoV-1 and MERS-CoV
infections diminishes the antigen-presenting ability of DCs to T cells. Also, declined production of antiviral cytokines like IFN-α, -β, and -γ and IL-12p40 with an up regulation in proinflammatory chemokines dictates the imbalance in the pro- and anti-inflammatory cytokines in patients with H7N9, SARS-CoV-1, MERS-CoV, and the current SARS-CoV-2 infections (137). C5a-C5aR axis thereby plays a critical role in mediating damage caused by highly pathogenic viruses.

COMPLEMENT EVASION BY RNA VIRUSES

The response of complement to RNA virus infection is potent enough to restrict these viruses. It might appear that the CS is insurmountable and can, therefore, tip the balance always in favor of the host. On the contrary, these viruses have evolved to adapt and have adopted unique strategies to limit the damaging effects of complement (Figure 2 and Table 2). Again, the limited genome in the case of RNA viruses is not a handicap as these viruses coexist with the host and exploit components from the host that favor their survival. This strategy strongly works in favor of enveloped RNA viruses; nonetheless, RNA viruses that lack envelope also possess certain characteristic features that help them counter the effects of complement. The sections below discuss the strategies adopted by RNA viruses to counter the effects of complement.

Viral Proteins as Complement Inhibitors

Non-enveloped RNA viruses lack the host-derived membrane but have unique mechanisms for targeting complement. Human astroviruses are icosahedral RNA viruses known to cause gastroenteritis. The direct association of the human astrovirus type 1 (HAstV-1) coat protein with C1q, an upstream component of CP, mediated the dissociation of C1s from the protease tetramer. This arrested the C1s cleavage, limiting the progression of the pathway, resulting in the decreased levels of C3b and C4b. The coat proteins of at least two other serotypes, HAstV-2 and HAstV-4, were also found to inhibit complement activation, suggesting that this inhibition was not restricted to HAstV-1 alone (138). Further investigations revealed that the inhibitory potential of the coat protein of HAstV-1 was not restricted to the CP but also included the LP by the direct binding of coat protein to MBL. The finding that the coat protein can inhibit C5a generation leading to a substantial reduction in C5b-9 holds clinical relevance as HAstV-1 infection causes gastroenteritis with a low inflammatory status in children (139). Hence, it is evident that the structural proteins in non-enveloped viruses can have direct modulatory effects on complement activation, thus limiting virus neutralization.

Proteins of enveloped viruses are also known to interact with key complement components and inhibit complement function. HCV belonging to the family Flaviviridae has a unique mechanism of modulating the CP. The NS 3/4A, a non-structural protein of HCV with protease activity, could directly bind and cleave the γ-subunit of C4, abrogating the effect of complement on the virus (140). The structural protein E2 in the bovine viral diarrhea virus has also been shown to block complement-mediated cell lysis, thereby acting as a potent inhibitor of complement (141). The NS1 protein secreted from the DENV-infected insect cells contains glycans rich in mannose. This secreted form of NS1 could also be identified in the saliva of DENV-infected A. aegypti mosquito. Independently, while DENV-NS1 could bind to C1s, C4, and C4BP, it was also found to bind to MBL, protecting the virus from neutralization by complement at the local sites of infection (142). WNV NS1 also binds to C1s and C4 and inactivate C4, thereby attenuating complement activation (143).

The matrix protein (M1) of influenza virus (A/WSN/33 strain) is an abundantly expressed protein in virus-infected cells and is released during necrosis to protect the newly formed virus particles from complement-mediated neutralization. The N-terminal domain of M1 binds to the globular head of C1q, blocking the interaction of IgG and C1q and thereby the CP (144).

Exploitation of the Complement Pathway Proteins

The main role of proteins associated with all the three complement pathways is to target pathogens including viruses, which, upon activation, facilitate virus neutralization. In many instances, these proteins have been found to be exploited by viruses to gain entry into cells, to replicate and utilize such cells as reservoirs, and to enhance virus spread. Many viruses preferentially exploit upstream components of the CP and LP like C1q and MBL to enhance infectivity and spread. The NS1 proteins of flaviviruses WNV, DENV, and yellow fever virus (YFV) have been shown to directly interact with C4, limiting the CP and LP. The NS1 protein directly binds to C4 and recruits C1s, the protease in the C1 complex, forming the C4–NS1–C1s complex that promotes active sequestration of C4, protecting the virus from the neutralizing effects of complement (143). Interaction of HCV core protein with gC1qR was found to have major implications in the immune responses to the virus (145–147).

Mannose binding lectins were found to enhance the infectivity of a range of RNA viruses including WNV, NiV, Hendra virus, and EBOV. Using EBOV glycoprotein pseudotyped lentivirus, it has been demonstrated that specific epitopes on the N-linked glycans of EBOV glycoproteins bound specifically to the carbohydrate recognition domain on MBL. Enhancement in virus uptake and infection due to MBL binding was found to be dependent on C1QB (gC1q receptor) (148). The binding of mucin like domain of EBOV (Zaire strain) glycoprotein to the fbrinogen-like recognition domain of ficolin-1, in the presence of limited complement, promoted virus entry rather than neutralization via the LP. The significance of this interaction is that ficolin-1 was found to enhance EBOV infection in an antibody- dependent manner (149).
Modulation of the Expression of Complement Components

RNA viruses have also been shown to down regulate the synthesis of complement proteins. HCV effectively puts a block in the progression of the complement pathway by transcriptionally regulating expression of critical components like C3, C4, C2, and C9 (150–153). Analysis of the liver tissue from chronic HCV patients showed a reduced expression of C4 mRNA. The NS5A protein of HCV was found to modulate the expression of two of the transcription factors, namely, upstream stimulating factor I (USF-1) and inhibiting interferon regulatory factor I (IRF-1), which are essential for either basal or IFN-γ-induced C4 expression (151). Similarly, HCV was also found to modulate C3 mRNA expression. The down regulation of farnesoid X receptor (FXR) by the HCV core protein weakly represses the C3 promoter activity, whereas NS5A protein, by inhibiting the expression of CAAT/enhancer binding protein beta (C/EBP-β), a transcription factor known to bind to the IL-1/IL-6 response element in the C3 promoter, strongly repressed IL-1β-induced C3 promoter activity. Thus, active modulation of C3 transcription factors by HCV results in the underexpression of C3 in chronic HCV patients (150). Both HCV and its core protein were found to repress C9 mRNA and protein expression. The core protein modulated T cell factor-4, the transcription factor regulating C9 promoter activity, resulting in the decreased levels of C9 mRNA in liver tissue and C5b-9 in the sera of chronic HCV patients (152). Marked decrease in C2 mRNA in chronic HCV infection also contributed to significantly low levels of CP C3 convertase (C4b2a). This resulted in a reduction of overall C3 turnover and diminished C3b deposition on target cells (153). HCV NS2 and NS5B proteins are also responsible for HCV-associated decrease in MHC class I chain-related protein A and B (MICA/B), resulting in a loss of the C3/C4 complement components. This inactivation of the CS leads to impairment of NK cell activation and attenuated adaptive immune response (154). Taken together, the potency of complement is reduced during HCV infection due to the active modulation of complement gene expression at the level of transcription. Besides modulation of complement components of the activation pathway, certain RNA viruses also modulate the expression of regulatory proteins or inhibitors of complement. Paramyxoviruses PIV5 and hRSV are known to up regulate the expression of CD55 (155) and CD59 (156). The up regulation of the regulatory proteins favors the virus as it can readily incorporate these proteins into their envelope during budding, limiting the neutralizing effect of complement.

Recruitment of Membrane-Associated Regulators

Enveloped RNA viruses acquire their envelope from the host during the process of virus egress. This, in many instances, turns out to be advantageous for the virus, as it also picks up the host proteins associated with the membrane, which can confer protection from the host complement. Widely reported host membrane-associated RCAs in the virus envelope include CD46, CD55, and CD59. RNA viruses including HIV-1, PIV5, MuV, NDV, and VSV are known to incorporate these RCAs into their
### TABLE 2 | Evasion strategies adopted by RNA viruses against the complement system.

| S.No. | Complement evasion strategy | Virus family and examples |
|-------|----------------------------|---------------------------|
| 1.    | Recruitment of membrane-associated regulators of complement activation | **Rhabdoviridae**  
Vesicular stomatitis virus (CD46, CD55)  
**Paramyxoviridae**  
Parainfluenza virus 5 (CD46, CD55)  
Newcastle disease virus (CD55, CD46)  
**Flaviviridae**  
Hepatitis C virus (CD59)  
**Retroviridae**  
Human immunodeficiency virus type 1 (CD46,CD55,CD59)  
Human T-cell leukemia virus type 1 (CD55,CD59) |
| 2.    | Incorporation of soluble regulators of complement activation | **Flaviviridae**  
Dengue virus (C4BP, Clusterin, Vitronectin)  
West Nile virus (fH, C4BP)  
Yellow fever virus (C4BP)  
**Retroviridae**  
Human immunodeficiency virus type 1 (fH) |
| 3.    | Virion-associated protease activity (F1-like activity) | **Paramyxoviridae**  
Nipah virus  
**Togaviridae**  
Chikungunya virus |
| 4.    | Exploitation of complement proteins as entry receptors | **Paramyxoviridae**  
Measles virus – Edmonston strain (CD46)  
**Picornaviridae**  
Echoviruses (CD55)  
Group B coxsackieviruses (CD55) |
| 5.    | Transcriptional regulation of complement proteins | **Flaviviridae**  
Hepatitis C virus (HCV down regulation of C2, C3 and C9)  
**Paramyxoviridae**  
Parainfluenza virus 5 (up regulation of CD56 and CD55)  
**Retroviridae**  
Human immunodeficiency virus type 1 (down regulation of CD59 and up regulation of C3 and C1q in the brain)  
**Pneumoviridae**  
Human respiratory syncytial virus (Up regulation of CD59 and CD55) |
| 6.    | Viral proteins as complement inhibitors | **Astroviridae**  
Human astrovirus 1 (Coat protein binds to C1q and arrests C1s)  
**Orthomyxoviridae**  
Influenza virus (A/WSN/33) M1 protein binds to C1q and blocks its interaction with IgG  
**Flaviviridae**  
Bovine viral diarrhea virus (E2 protein)  
Hepatitis C virus (NS3/4A binds to C4, cleaves γ subunit) |

Extensive studies on the virus-associated CD46 and CD55 show that they are functional, with CD46 acting as a cofactor for the Fc-mediated cleavage of C3b into iC3b, and CD55, accelerating the decay of complement convertases protecting these viruses from complement (60, 159). HCV particles generated from hepatic cells were found to harbor CD59, an inhibitor of the terminal pathway of complement. CD59 associated with the virion conferred protection to the virus from antibody-dependent complement-mediated lysis. Addition of CD59 blockers to both cell line derived and plasma primary virions resulted in substantial virolysis in the presence of complement, which highlights the significance of CD59 in protecting HCV from complement (160).

Human immunodeficiency virus 1 incorporates CD46, CD55, and CD59 into the virus envelope during egress. The presence or absence of the RCAs in the virus envelope depended on the cell type in which the virus was generated. The levels of RCA incorporated into the virus envelope dictated the extent of neutralization. When sensitized with gp160 antibodies, only those viruses generated in cell lines underwent virolysis; however, primary HIV isolates required sensitization with anti-RCA antibodies to undergo virolysis by complement. Besides the primary isolates of HIV-1 and specific cell line-derived HIV, (SIV delta/B670) was also found to incorporate all three RCAs. The protective role of the RCAs in limiting the effect of complement on HIV is well evidenced from the findings that HIV cultured in CHO cells with individual RCAs was significantly protected from complement-mediated virolysis compared to those without the regulators (157, 158, 161–163). Human T cell leukemia/lymphoma oncovirus type I (HTLV-1) cultured in MT2 cells contained both CD55 and CD59 in the virus envelope. The incorporated RCAs protected the particles from complement-mediated neutralization. However, this was reversed when the particles were treated with anti-CD55 and anti-CD59 antibodies.
or phospholipase C (164). Although it could well be considered that incorporation is a random process, growing evidences as in the case of HCV, RSV, and PIV5 suggest the recruitment of CD55 and/or CD59 to be more specific in nature because the respective virus infection induced up regulation of the RCAs in infected cells (155, 156, 165, 166).

Recruitment of Soluble Regulators

RNA viruses not only incorporate membrane bound RCAs but also recruit soluble RCAs. The NS1 protein of DENV, WNV, and YFV were all found to recruit C4BP, an RCA of the CP (167), while other complement regulators reported to bind to NS1 include fH (168), clusterin (169), and vitronectin (170). The secreted WNV NS1 protein recruits soluble fH either in solution or onto the cell surface, as NS1 is known to bind back to cell surface. The fH thus recruited acted as a cofactor for the factor I-mediated cleavage of C3b into iC3b. The fH bound to NS1 protein can rapidly regulate complement in solution and limit complement deposition and damage to the virus and virus-infected cells (168). It can also restrict both CP and LP by binding to C4BP and inactivating C4b, both on the cell surface and in solution (167). Recruitment of soluble RCAs by NS1 protein is not pan-flavivirus as it has been demonstrated that the NS1 protein of JEV was incapable of recruiting fH (44). As mentioned above, the NS1 protein of at least three flaviviruses binds to C4BP and acts as a cofactor for the inactivation of C4b into C4c and C4d both in solution and on the cell surface. The binding site of NS1 on C4BP was mapped to the α-chain of C4BP (167). The DENV NS1 protein can also interact with clusterin, an important regulator of the terminal pathway of complement. This interaction prevents the assembly of MAC and thereby, virolysis (169). The NS1 protein of flaviviruses, including DENV2, ZIKV, and WNV, has been shown to play a role in inhibiting the terminal pathway of complement by inhibiting C9 polymerization. Additionally, the NS1 protein of DENV-2 was found to bind to vitronectin, a regulator of the terminal complement pathway and block C9 polymerization and MAC assembly (170). Among the retroviruses, HIV is known to recruit fH with the binding target being the Env proteins gp120 and gp41 (171–173). Factor H was found to have a dominant role in protecting HIV from complement. This is highlighted by the finding that even in the presence of anti-HIV antibodies, HIV was not neutralized by NHS but was neutralized by fH-deficient serum. The neutralizing effect of complement in NHS could be restored only upon inhibiting the interaction of fH with gp41, using a specific blocking monoclonal antibody against the fH binding site on gp41 (173).

Most of the evasion strategies described above involved recruitment of either membrane-associated or soluble RCAs and inhibitors of complement. Factor I is an important and unique serine protease involved in the regulatory arm of the complement. Factor I mediates the inactivation of C3b into iC3b or C3c and C3d, and C4b into C4c and C4d in the presence of specific cofactors. Earlier we had discussed that NIV exhibits an fH-like activity that could inactivate C3b but not C4b. Only the first order of C3b inactivation, which is the conversion of C3b into iC3b, was supported by the NIV-associated fH-like activity. Conversion of C3b into iC3b occurred with the incubation of C3b, fH, or sCR1 and wtNiV without the addition of fI. CD46 was also found to be associated with wtNiV, but interestingly, the associated CD46 was incapable of inactivating C3b into iC3b even with the addition of fI (72). More recently, it was identified that CHIKV also has an fH-like activity that contributes to its complement resistance. However, a stark difference was that the CHIKV-associated fH-like activity supported only the fH and not CD35-mediated inactivation of C3b into iC3b. Like NIV, CHIKV-associated fH-like activity was incapable of inactivating C4b. Although electron microscopic analysis pointed to an association of fI to the CHIKV envelope, immunoblotting and function blocking cofactor activity assays with an antibody targeting fI protease activity showed that CHIKV-associated fH-like activity is not of host origin (57). Since the source of fH or fH-like activity is not yet determined at least in the case of CHIKV, detailed investigations are required to gain a better understanding on the precise mechanisms involved.

Complement Proteins as Tools for Virus Attachment and Entry

Receptor usage is a key factor that determines the host range in many viruses. Viruses using RCAs to attach to and infect cells have been widely reported among the members of the Picornaviridae family. Many subtypes of echoviruses like echo-6, -7, -11, -12, -20, and -21 bind to CD55 to gain access into the cell (174) and further studies established the binding site of echo-7 virus to CCPs 2–4 of CD55 (175). In contrast, many types of coxsackieviruses and enterovirus 70 also bind to CD55, but this attachment did not directly facilitate virus entry (176–179). Group B coxsackieviruses (CVBs) binding to CD55 on the apical surface of cells resulted in the clustering of CD55. This activated Abl kinases, resulting in actin remodeling, which delivers the virus to the tight junctions. At the tight junction, it interacts with the coxsackievirus and adenovirus receptor (CAR), leading to the internalization and the subsequent uncoating and replication (180). The Edmonston strain of measles virus uses all four isoforms of CD46 as its cellular receptor binding to CCP-1 and -2 with hemagglutinin being the interacting viral surface glycoprotein (181–185). CR3 and CR4 are used by hantavirus (186) for entry, while CR4 is exploited by rotavirus (187).

CONCLUDING REMARKS

Complement–RNA virus interactions are complex, with each remaining in the cross hairs of the other. The role of the CS is undeniably that of a barrier at all levels of virus infection, with RNA viruses facing stiff resistance from the very early stages of infection. Infection with RNA viruses mostly begins locally, while other complement regulators reported to bind to NS1 include fH (168), clusterin (169), and vitronectin (170). The secreted WNV NS1 protein recruits soluble fH either in solution or onto the cell surface, as NS1 is known to bind back to cell surface. The fH thus recruited acted as a cofactor for the factor I-mediated cleavage of C3b into iC3b. The fH bound to NS1 protein can rapidly regulate complement in solution and limit complement deposition and damage to the virus and virus-infected cells (168). It can also restrict both CP and LP by binding to C4BP and inactivating C4b, both on the cell surface and in solution (167). Recruitment of soluble RCAs by NS1 protein is not pan-flavivirus as it has been demonstrated that the NS1 protein of JEV was incapable of recruiting fH (44). As mentioned above, the NS1 protein of at least three flaviviruses binds to C4BP and acts as a cofactor for the inactivation of C4b into C4c and C4d both in solution and on the cell surface. The binding site of NS1 on C4BP was mapped to the α-chain of C4BP (167). The DENV NS1 protein can also interact with clusterin, an important regulator of the terminal pathway of complement. This interaction prevents the assembly of MAC and thereby, virolysis (169). The NS1 protein of flaviviruses, including DENV2, ZIKV, and WNV, has been shown to play a role in inhibiting the terminal pathway of complement by inhibiting C9 polymerization. Additionally, the NS1 protein of DENV-2 was found to bind to vitronectin, a regulator of the terminal complement pathway and block C9 polymerization and MAC assembly (170). Among the retroviruses, HIV is known to recruit fH with the binding target being the Env proteins gp120 and gp41 (171–173). Factor H was found to have a dominant role in protecting HIV from complement. This is highlighted by the finding that even in the presence of anti-HIV antibodies, HIV was not neutralized by NHS but was neutralized by fH-deficient serum. The neutralizing effect of complement in NHS could be restored only upon inhibiting the interaction of fH with gp41, using a specific blocking monoclonal antibody against the fH binding site on gp41 (173).

Most of the evasion strategies described above involved recruitment of either membrane-associated or soluble RCAs and inhibitors of complement. Factor I is an important and unique serine protease involved in the regulatory arm of the complement. Factor I mediates the inactivation of C3b into iC3b or C3c and C3d, and C4b into C4c and C4d in the presence of specific cofactors. Earlier we had discussed that NIV exhibits an fH-like activity that could inactivate C3b but not C4b. Only the first order of C3b inactivation, which is the conversion of C3b into iC3b, was supported by the NIV-associated fH-like activity. Conversion of C3b into iC3b occurred with the incubation of C3b, fH, or sCR1 and wtNiV without the addition of fI. CD46 was also found to be associated with wtNiV, but interestingly, the associated CD46 was incapable of inactivating C3b into iC3b even with the addition of fI (72). More recently, it was identified that CHIKV also has an fH-like activity that contributes to its complement resistance. However, a stark difference was that the CHIKV-associated fH-like activity supported only the fH and not CD35-mediated inactivation of C3b into iC3b. Like NIV, CHIKV-associated fH-like activity was incapable of inactivating C4b. Although electron microscopic analysis pointed to an association of fI to the CHIKV envelope, immunoblotting and function blocking cofactor activity assays with an antibody targeting fI protease activity showed that CHIKV-associated fH-like activity is not of host origin (57). Since the source of fH or fH-like activity is not yet determined at least in the case of CHIKV, detailed investigations are required to gain a better understanding on the precise mechanisms involved.
These initial interactions set the stage for sequential progress of the complement cascade promoting virus neutralization. Yet again, marked variations exist even among closely related viruses with regard to the mechanism of neutralization (Table 1) [27, 60, 61]. Although it may be anticipated that surface glycoproteins could contribute to these differences, in-depth investigations into these interactions are required to better understand their role. Another key aspect is the damaging effect the CS imparts on the host during the process of virus clearance. Hyperactivation of complement during infection by certain members of the Togaviridae, Flaviviridae, and Coronaviridae plays a key role in disease severity. The cross-talk between complement and other components of the immune system during RNA virus infection plays a pivotal role in the overall pathogenesis, with the latest example being complement-mediated disease enhancement in SARS-CoV-2 infection. Thus, RNA viruses appear to be in the cross hairs of complement.

The big question that arises out of RNA virus–complement interactions is how these viruses productively infect and cause diseases in the host, overcoming complement. Both enveloped and non-enveloped RNA viruses have ingenious ways of limiting complement. Many DNA viruses including poxviruses and γ-herpes viruses have a large genome that supports expression of viral homologs that mimic the functions of complement regulatory proteins. RNA viruses might appear at a disadvantage with respect to its genome size; however, they are known to thwart complement in multiple ways. One well-studied mechanism is the recruitment of the host RCAs by enveloped RNA viruses. The protective effect of these RCAs on the virus is very significant, especially at the local sites of infection. Another area requiring significant investigation is the nature of incorporation of the RCAs. Detailed investigation is required to further understand the specificity or selectivity of incorporation of these RCAs.

The evasion strategies adopted by RNA viruses bring the CS in the cross hairs of the virus. It is clear that the balance is quite delicate and can tip to any side, as is evidenced in the case of flaviviruses like DENV and more recently in SARS-CoV-2. Approaches to combat SARS-CoV-2, although not proven completely, include targeting complement activation to better manage the disease symptoms. Exploitation of RNA viruses as vaccine and oncolytic vectors is an emerging field. Viral vectors should be attenuated enough so as to not cause disease but yet be capable of productively infecting the target cells. An attenuated vector harboring RCAs would be a better candidate to bypass complement yet meet the requirements. Thus, a rational approach to develop therapeutics, inhibitors, or viral vectors should also take the role of complement into consideration. In conclusion, studies have highlighted the complexities in RNA virus–complement interactions, but with emerging viruses, a constant pursuit is required to better understand these interactions.

AUTHOR CONTRIBUTIONS

NK, UK, and JJ conceived the concept for this review article. NK, UK, ST, and JJ wrote the manuscript. NK, UK, ST, and JJ read, edited, and reviewed the manuscript. All authors contributed to the article and approved the submitted version.

FUNDING

This work was supported by the Department of Biotechnology-Ramalingaswami Fellowship, BT/RLF/Re-entry/29/2012, and Department of Biotechnology–Rajiv Gandhi Center for Biotechnology Intramural funds (to JJ). NK acknowledges funding from the Council of Scientific & Industrial Research (CSIR), India [09/716(0174)/2017-EMR-1] and UK, the University Grants Commission/Council of Scientific & Industrial Research (UGC/CSIR), India [19/06/2016(i)EU-V]

ACKNOWLEDGMENTS

We thank Prof. M. Radhakrishna Pillai, Director, RGCB, for his constant support.

REFERENCES

1. Kolev M, Kemper C. Keeping it all going-complement meets metabolism. Front Immunol. (2017) 8:1. doi: 10.3389/fimmu.2017.00001
2. Lubbers R, van Essen ME, van Kooten C, Trouw LA. Production of complement components by cells of the immune system. Clin Exp Immunol. (2017) 188:183–94. doi: 10.1111/cei.12952
3. Morgan BP, Gasque P. Extrahepatic complement biosynthesis: where, when and why? Clin Exp Immunol. (1997) 107:1–7. doi: 10.1046/j.1365-2249.1997.00180.x
4. Bajic G, Degn SE, Thiel S, Andersen GR. Complement activation, regulation, and molecular basis for complement-related diseases. EMBO J. (2015) 34:2735–57. doi: 10.15252/embj.201591881
5. Walport MJ. Complement. First of two parts. N Engl J Med. (2001) 344: 1058–66.
6. Carroll MV, Sim RB. Complement in health and disease. Adv Drug Deliv. Rev. (2011) 63:965–75.
7. Ricklin D, Reis ES, Lambris JD. Complement in disease: a defence system turning offensive. Nat Rev Nephrol. (2016) 12:383–401. doi: 10.1038/nrneph.2016.70
8. Schwaeble W, Dahl MR, Thiel S, Stover C, Jensenius JC. The mannan-binding lectin-associated serine proteases (MASPs) and MAP19: four components of the lectin pathway activation complex encoded by two genes. Immunobiology. (2002) 205:455–66. doi: 10.1078/0171-2985-00146
9. Fearon DT, Austen KF, Ruddy S. Formation of a hemolytically active cellular intermediate by the interaction between properdin factors B and D and the activated third component of complement. J Exp Med. (1973) 138:1305–13. doi: 10.1084/jem.138.6.1305
10. Le GE, Abbenante G, Fairlie DP. Profiling the enzymatic properties and inhibition of human complement factor B. J Biol Chem. (2007) 282:34809–16. doi: 10.1074/jbc.m705646200
11. Pillmer L, Blum L, Lepow IH, Ross OA, Todd EW, Wardlaw AC. The properdin system and immunity. I. Demonstration and isolation of a new serum protein, properdin, and its role in immune phenomena. Science. (1954) 120:279–85. doi: 10.1126/science.120.3112.279
26. Sissons JG, Cooper NR, Oldstone MB. Alternative complement pathway-
mediated virus neutralization by the fusion protein of measles virus.
*J Virol.* (2005) 79:4393–403. doi: 10.1128/jvi.01850-08

27. Johnson JB, Capraro GA, Parks GD. Differential mechanisms of
complement-mediated neutralization of measles virus by normal human sera: mechanisms involving antibody and complement. *J Immunol.* (1991) 147:1317–22.

28. Hirsch RL, Wolinsky JS, Winkelstein JA. Activation of the alternative
complement pathway by the fusion protein of measles virus. *J Virol.* (1988) 62:3929–36. doi: 10.1128/jvi.62.10.3929-3936.1988

29. Johnson JB, Schmitt AP, Parks GD. Point mutations in the paramyxovirus
F protein that enhance fusion activity shift the mechanism of complement-
mediated virus neutralization. *J Virol.* (2013) 87:9250–9. doi: 10.1128/jvi.01111-13

30. Biswas M, Johnson JB, Kumar SR, Parks GD, Elankumaran S. Incorporation of host complement regulatory proteins into Newcastle disease virus enhances complement evasion. *J Virol.* (2012) 86:12708–16. doi: 10.1128/jvi.00846-12

31. Welsh RM. Host cell modification of lymphocytic choriomeningitis virus and Newcastle disease virus altering viral inactivation by human complement. *J Immunol.* (1977) 118:348–54.
Prohaszka Z, Hidvegi T, Ujhelyi E, Stoiber H, Dierich MP, Susal C, Spear GT, Sullivan BL, Takefman DM, Landay AL, Lint TF. Human mannose binding lectin (MBL) and complement component C1q inhibits the infectivity of cell-free HTLV-I. J Immunol. (1998) 161:5712–9.

Johnson JB, Borisevich V, Rockx B, Parks GD. A novel factor I activity in Nipah virus inhibits human complement pathways through cleavage of C3b. J Virol. (2015) 89:899–98. doi: 10.1128/jvi.02427-14

Aaskov JG, Hadding U, Bitter-Suermann D. Interaction of Ross River virus with the complement system. J Gen Virol. (1985) 66(Pt 1):121–9. doi: 10.1128/jvi.0022-1317.66.1-121

Morrison TE, Fraser RJ, Smith PN, Malahangim S, Heise MT. Complement contributes to inflammatory tissue destruction in a mouse model of Ross River virus-induced disease. J Virol. (2007) 81:5132–43. doi: 10.1128/jvi.02799-06

Gunn BM, Jones JE, Shabman RS, Whitmore AC, Sarkar S, Blevins LK, et al. Ross River virus envelope glycan contributes to disease through activation of the classical complement pathway in rabbit, mouse and guinea-pig sera; resistance of mumps virus and vesicular stomatitis virus to neutralization. J Virol. (1991) 77:377–82.

Ip WK, Chan KH, Law HK, Tso GH, Kong EK, Wong WH, et al. Mannose-binding lectin through multiple mechanisms. J Virol. (2010) 84:8753–64. doi: 10.1128/jvi.00554-10

Pang RT, Poon TC, Chan KC, Lee NL, Chiu RW, Tong YK, et al. Serum proteomic fingerprints of adults patients with severe acute respiratory syndrome. Clin Chem. (2006) 52:421–9. doi: 10.1373/dichem.2005.061689

Gao T, Hu M, Zhang X, Li H, Zhu L, Liu H, et al. Highly pathogenic coronavirus N protein aggravates lung injury by MASP-2-mediated complement activation. MedRxiv. [Preprint]. (2020). doi: 10.1102/l87629219

Magro C, Mulvey JJ, Berlin D, Nuovo G, Salvatore S, Harp J, et al. Complement associated microvascular injury and thrombosis in the pathogenesis of severe COVID-19 infection: a report of five cases. Transl Res. (2020) 220:1–13. doi: 10.1016/j.trsl.2020.04.007

Noris M, Benigni A, Remuzzi G. The case of complement activation in COVID-19 multiorgan impact. Kidney Int. (2020) 98:314–22. doi: 10.1016/j.kint.2020.05.013

Morrison TE, Simmons JD, Heise MT. Complement receptor 3 promotes severe rose river virus-induced disease. J Virol. (2008) 82:11263–72. doi: 10.1128/jvi.01352-08

Malasit P. Complement and dengue haemorrhagic fever/shock syndrome. Southeast Asian J Trop Med Public Health. (1987) 18:316–20.

Bokisch VA, Muller-Eberhard HJ, Dixon FI. The role of complement in hemorrhagic shock syndrome (dengue). Trans Assoc Am Phys. (1973) 86:102–10

Bokisch VA, Top FH Jr., Russell PK, Dixon FI, Muller-Eberhard HJ. The potential pathogenic role of complement in dengue hemorrhagic shock syndrome. N Engl J Med. (1973) 289:996–1000. doi: 10.1056/nejm197311082891902

Fuchs A, Pinto AK, Schwaebel WJ, Diamond MS. The lectin pathway of complement activation contributes to protection against West Nile virus infection. J Virol. (2011) 85:101–9. doi: 10.1128/jvi.02001-11

Avirutpan P, Hauhart RE, Marovich MA, Garred P, Atkinson JP, Diamond MS. Complement-mediated neutralization of dengue virus requires mannose-binding lectin. mBio. (2011) 2:e00276-11.

Mehlhop E, Diamond MS. Protective immune responses against West Nile virus are primed by distinct complement activation pathways. J Exp Med. (2006) 203:1371–81. doi: 10.1084/jem.20052388

Mehlhop E, Fuchs A, Engle M, Diamond MS. Complement modulates pathogenesis and antibody-dependent neutralization of West Nile virus infection through a C5-independent mechanism. J Virol. (2009) 83:11–5. doi: 10.1128/jvi.2009.08.019

Schiela B, Bernklau S, Malekshahi Z, Deutschmann D, Koske I, Ranki Z, et al. Active human complement reduces the Zika virus load via formation of the membrane-attack complex. Front Immunol. (2018) 9:2177.

Hirsch RL, Griffin DE, Winkelstein JA. Host modification of Sindbis virus sialic acid content influences alternative complement pathway activation and virus clearance. J Immunol. (1981) 127:1740–3.

Hirsch RL, Griffin DE, Winkelstein JA. Role of complement in viral infections: participation of terminal complement components (C5 to C9) in recovery of mice from Sindbis virus infection. Infect Immun. (1980) 30:899–901.

Nag J, Mukesh RK, Suma SM, Kunnakkadan U, Kumar NA, Johnson JB. A Factor H-Like activity associated with chikungunya virus contributes to its resistance to the human complement system. J Virol. (2020) 94:e0262-2019.

Mills BJ, Beebe DP, Cooper NR. Antibody-independent neutralization of vesicular stomatitis virus by human complement. II. Formation of VSV-lipoprotein complexes in human serum and complement-dependent viral lysis. J Immunol. (1979) 123:2518–24.

Beebe DP, Cooper NR. Neutralization of vesicular stomatitis virus (VSV) by human complement requires a natural IgM antibody present in human serum. J Immunol. (1981) 126:1562–8.

Johnson JB, Lyles DS, Alexander-Miller MA, Parks GD. Virion-associated complement regulator CD55 is more potent than CD46 in mediating resistance of mumps virus and vesicular stomatitis virus to neutralization. J Virol. (2012) 86:9929–40. doi: 10.1128/jvi.01154-12

Kunnakkadan U, Nag J, Kumar NA, Mukesh RK, Suma SM, Johnson JB. Complement-mediated neutralization of a potent neurotropic human pathogen, chandipura virus, is dependent on C1q. J Virol. (2019) 93:e994–919.

Ji X, Olinger GG, Aris S, Chen Y, Gewurz H, Spear GT. Mannose-binding lectin through multiple mechanisms. J Virol. (1991) 75:377–82.
104. Chong YH, Lee MJ. Expression of complement inhibitor protein CD59 in human melanoma cells. *J Immunol.* (2000) 164:2392–9. doi: 10.4049/jimmunol.164.4.2392

105. Steoer MA, Morrison TE. Complement and viral pathogenesis. *Virology.* (2011) 411:362–73. doi: 10.1016/j.virology.2010.12.045

106. El-Shamy A, Branch AD, Schiano TD, Gorevic PD. The complement system and C1q in chronic hepatitis C virus infection and mixed cryoglobulinemia. *Front Immunol.* (2010) 9:101.

107. Fauci AS, Bassyouni HJ, Hamdy A, Foad NA, Wali JE. Anti-C1q in chronic hepatitis C virus genotype IV infection: association with autoimmune rheumatologic manifestations. *Immunol. Invest.* (2015) 44:45–55. doi: 10.3109/08820319.2014.932378

108. Saadoun D, Siddall S, Trendelenburg M, Limal N, Sene D, Piette J, et al. Anti-C1q antibodies in hepatitis C virus infection. *Clin Exp Immunol.* (2006) 145:128–132. doi: 10.1111/j.1600-0385.2006.03153.x

109. Bosmann M. Complement activation during critical illness: current findings and an outlook in the Era of COVID-19. *Am J Respir Crit Care Med.* (2020) 202:163–5. doi: 10.1164/rccm.202005-1926ed

110. Kim AH, Dimitriou JD, Holland MC, Mastellos D, Mueller YM, Altman JD, et al. Complement C5a receptor is essential for the optimal generation of antiviral CD8+ T cell responses. *J Immunol.* (2004) 173:2529–9. doi: 10.4049/jimmunol.173.4.2529

111. Chen Y, Li X, Tian L, Zheng S, Yang S, Dong Y, et al. Dynamic behavior of lymphocyte subgroups correlates with clinical outcomes in human H7N9 infection. *J Infect.* (2014) 69:358–65. doi: 10.1111/jinf.2014.05.006

112. Diao H, Cui G, Wei Y, Chen J, Zuo J, Cao H, et al. Severe H7N9 infection is associated with decreased antigen-presenting capacity of CD14+ cells. *PLoS One.* (2014) 9:e92823. doi: 10.1371/journal.pone.0092823

113. Guo BE, Ward PA. Role of CsA in inflammatory responses. *Annu Rev Immunol.* (2005) 23:821–52. doi: 10.1146/annurev.immunol.23.042403.121200

114. Domej W, Oettl K, Renner W. Oxidative stress and free radicals in COPD–implications and relevance for treatment. *Int J Chronic Obstructive Pulm. Dis.* (2014) 9:1207–24. doi: 10.2147/copd.s11226

115. Aikaie T, Ando M, Oda T, Doi T, Ijiri S, Araki S, et al. Dependence on O2-generation by xanthine oxidase of pathogenesis of influenza virus infection in mice. *J Clin Invest.* (1990) 85:73–49. doi: 10.1172/jci14499

116. Song N, Li P, Jiang Y, Sun H, Cui J, Zhao G, et al. C5a receptor1 inhibition alleviates influenza virus-induced acute lung injury. *Int Immunopharmac.* (2018) 59:12–20. doi: 10.1016/j.intimp.2018.03.029

117. Ling MT, Tu W, Han Y, Mao H, Chong WP, Guan J, et al. Mannose-binding lectin contributes to deleterious inflammatory response in pandemic H1N1 and avian H9N2 infection. *J Infect Dis.* (2012) 205:44–53. doi: 10.1086/677119

118. Polyak SJ, Klein KC, Shoii J, Miyamura T, Lingappa JR. Assemble and interact: pleiotropic functions of the HCV core protein. In: Tan SL editor. *Hepatitis C Viruses: Genomes and Molecular Biology. Norfolk: Horizon Bioscience.* (2006)

119. Waggoner SN, Hall CH, Hahn YS. HCV core protein interaction with gC1q receptor inhibits TH1 differentiation of CD4+ T cells via suppression of dendritic cell IL-12 production. *J Leukoc Biol.* (2007) 82:1407–19. doi: 10.1189/jlb.1105257

120. Cummings KL, Rosen HR, Hahn YS. Frequency of gC1qR+CD4+ T cells increases during acute hepatitis C virus infection and remains elevated in patients with chronic infection. *Clin Immunol.* (2009) 132:401–11. doi: 10.1016/j.clim.2009.05.002

121. Fausther-Bovendo H, Vieillard V, Sagan S, Bismuth G, Debre P. HIV gp41 engages gC1qR on CD4+ T cells to induce the expression of an NK ligand through the PI3K/H2O2 pathway. *PLoS Pathog.* (2010) 6:e1000975. doi: 10.1371/journal.ppat.1000975

122. Montefiori DC, Graham BS, Zhou JT, Zhou JY, Ahearn JM. Binding of human immunodeficiency virus type 1 to the C3b/C4b receptor CR1 (CD35) and red blood cells in the presence of envelope-specific antibodies and complement. *J Virol.* (2004) 78:145–52. doi: 10.1128/jvi.78.1.145-152.2004

123. Weiss L, Okada N, Haefner-Cavallon N, Hattori T, Faucher C, Kazatchkine MD, et al. Decreased expression of the membrane inhibitor of complement-mediated cytolysis CD59 on T lymphocytes of HIV-infected patients. *AIDS.* (1992) 6:379–85. doi: 10.1097/00002030-199206000-00004

124. Moir S, Malaspina A, Li Y, Chun TW, Lowe T, Adelsberger J, et al. B cells of HIV-1-infected patients bind virions through CD21-complement interactions and transmit infectious virus to activated T cells. *J Exp Med.* (2000) 192:637–46. doi: 10.1084/jem.192.5.637
Bajtay Z, Speth C, Erdelj A, Dierich MP. Cutting edge: productive HIV-1 infection of dendritic cells via complement type 3 (CR3, CD11b/CD18). J Immunol. (2004) 173:4775–8. doi: 10.4049/jimmunol.173.8.4775

Banki Z, Posch W, Ejas A, Oberhauser V, Willey S, Gassner C, et al. Complement as an endogenous adjuvant for dendritic cell-mediated induction of retrovirus-specific CTLs. PLoS Pathog. (2010) 6:e1000891. doi: 10.1371/journal.ppat.1000891

Borrow P, Lewicki H, Hahn BH, Shaw GM, Oldstone MB. Virus-specific Banki Z, Posch W, Ejaz A, Oberhauser V, Willey S, Gassner C, et al. Complement as an endogenous adjuvant for dendritic cell-mediated induction of retrovirus-specific CTLs. PLoS Pathog. (2010) 6:e1000891. doi: 10.1371/journal.ppat.1000891

Chauhan AJ, Wiffen LJ, Brown TP. COVID-19: a collision of complement, coagulation and inflammatory pathways. J Transl Med. (2020) 18:2110–7. doi: 10.1186/s12967-020-04981-0

Cukrowski M, Yantosca LM, Holguin MH, Parker CJ, Spear GT. Human immunodeficiency virus type 1 incorporates both glycosyl phosphatidylinositol-anchored CD55 and CD59 to parainfluenza Virus 5 inhibition of complement-mediated neutralization. J Virol. (2016) 90:5256–69. doi: 10.1128/jvi.00032-16

Driesen E, Tackx E, Van den Bossche E, Van Boven M, Van Damme J. Inhibition of major histocompatibility complex Class I antigen presentation by hepatitis C virus core protein in myeloid dendritic cells. J Virol. (2009) 83:10596–606. doi: 10.1128/jvi.00914-09

Dreier S, Haider N, Koster S, Pfeifer M, Schlesinger M, Meder J, et al. CD59, CD46, and CD55 to parainfluenza Virus 5 inhibition of complement-mediated neutralization. J Virol. (2016) 90:5256–69. doi: 10.1128/jvi.00032-16

Elsaesser A, Löffler D, Grellner S, Lauer G, Roeser A, Wiedenmann B, et al. A novel role for the receptor of the complement cleavage fragment C5a, C5aR1, in CCR5-mediated entry of HIV into macrophages. AIDS Res Hum Retroviruses. (2016) 32:399–408. doi: 10.1089/aid.2015.0099

Hair PS, Gronemus JQ, Crawford KB, Salvi VP, Cunnion KM, Thielens NM, et al. Antibodies attenuate the capacity of dendritic cells to stimulate HIV-specific cytotoxic T lymphocytes. J Infect Dis. (2015) 212:44–56. doi: 10.1093/infdis/jiv302

Kim H, Meyer K, Di Bisceglie AM, Ray RB, et al. Hepatitis C virus proteins inhibit C3 complement production. J Virol. (2012) 86:2221–8. doi: 10.1128/jvi.06577-11

Kumar et al. 2020 | Volume 11 | Article 573583

Kunstfeld B, Gerlich W, Bals R, St Leger S, Hille R, et al. A novel role for the receptor of the complement cleavage fragment C5a, C5aR1, in CCR5-mediated entry of HIV into macrophages. AIDS Res Hum Retroviruses. (2016) 32:399–408. doi: 10.1089/aid.2015.0099

Kuciel M, Biernacka I, Jaskulska M, Szczepaniak E, Gospodarek U, et al. Inhibition of complement activity by hepatitis C virus as an additional lesion in the regulation of complement components. PLoS One. (2014) 9:e101422. doi: 10.1371/journal.pone.0101422

Kuiper AH, Velghe M, Van den Bossche E, Van Damme J, Schuurman R, et al. Antibodies attenuate the capacity of dendritic cells to stimulate HIV-specific cytotoxic T lymphocytes. J Infect Dis. (2015) 212:44–56. doi: 10.1093/infdis/jiv302

Kurz A, Wilig P, Jansen C, Enders C, Steinhagen M, et al. Hepatitis C virus proteins inhibit C3 complement production. J Virol. (2012) 86:2221–8. doi: 10.1128/jvi.06577-11

Ling Xi, Wang Y, Wang L, Zhang H, et al. Inhibition of the classical complement pathway through interacting with C1qA. J Virol. (2016) 90:2571–8. doi: 10.1128/jvi.014316-0

Loukili NH, Casteilla L, Neumann I, Larabi M, et al. Secreted NS1 protects dengue virus from mannose-binding lectin-mediated neutralization. J Immunol. (2016) 197:4053–65. doi: 10.4049/jimmunol.1600323

Oztekin M, Södroski J, Wurzner R, Dierich MP. Decay-accelerating factor (CD55) protects human immunodeficiency virus type 1 from inactivation by highly pathogenic avian influenza H5N1 virus infection. Am J Respir Cell Mol Biol. (2013) 49:221–30. doi: 10.1165/rcmb.2012-0428oc

Posch W, Cardinaud S, Hamimi C, Fletcher A, Muelbacher A, Losacker K, et al. Antibodies attenuate the capacity of dendritic cells to stimulate HIV-specific cytotoxic T lymphocytes. J Allergy Clin Immunol. (2012) 130:1368–74.e2.

Posch W, Steger M, Knackmuss U, Blatter M, Baldauf HM, Doppler W, et al. Complement-sonopsonized HIV-1 overcomes restriction in dendritic cells. PLoS Pathog. (2015) 11:e1005005. doi: 10.1371/journal.ppat.1005005

Sun S, Zhao G, Liu C, Wu X, Guo Y, Yu H, et al. Inhibition of complement activation alleviates acute lung injury induced by highly pathogenic avian influenza H5N1 virus infection. Am J Respir Cell Mol Biol. (2013) 49:221–30. doi: 10.1165/rcmb.2012-0428oc

Wang R, Xiao H, Guo R, Li Y, Shen B. The role of C5a in acute lung injury induced by highly pathogenic viral infections. Emerging Microbes Infect. (2015) e2.e28.
targets for vaccine protection. Virology. (1994) 205:82–92. doi: 10.1006/viro.1994.1622
162. Saifuddin M, Parker CJ, Peeples ME, Gorny MK, Zolla-Pazner S, Ghassemi M, et al. Role of virion-associated glycosylphosphatidylinositol-linked proteins CD55 and CD59 in complement resistance of cell line-derived and primary isolates of HIV-1. J Exp. Med. (1995) 182:501–9. doi: 10.1084/jem.182.2.501
163. Schmitz J, Zimmer JP, Kluxen B, Aries S, Bogel M, Gigli I, et al. Antibody-dependent complement-mediated cytotoxicity in sera from patients with HIV-1 infection is controlled by CD55 and CD59. J Clin Invest. (1995) 96:1520–6. doi: 10.1172/jci118190
164. Spear GT, Lurain NS, Parker CJ, Ghassemi M, Payne GH, Saifuddin M, et al. HIV glycoprotein 41 nonstructural protein 1.
165. Avirutnan P, Hauhart RE, Somnuke P, Blom AM, Diamond MS, Atkinson JP. Binding of flavivirus nonstructural protein NS1 to C4b binding protein activaton by binding the regulatory protein factor H.
166. Karnauchow TM, Dawe S, Lublin DM, Dimock K. Short consensus repeat domain 1 of decay-accelerating factor is required for enterovirus 70 binding. J Virol. (1998) 72:9380–3.
167. Shafren DR, Tolson DL, Harrison BA, Altman E, Lublin DM, Dimock K. The HeLa cell receptor for enterovirus 70 is decay-accelerating factor (CD55). J Virol. (1996) 70:5143–52.
168. Roydhouse AJ, Kunnakkadan NA, Thomas J, Johnson GS. The HeLa cell receptor for enterovirus 70 is decay-accelerating factor (CD55). J Virol. (1996) 70:5143–52.
169. Karnauchow TM, Tolson DL, Harrison BA, Altman E, Lublin DM, Dimock K. The HeLa cell receptor for enterovirus 70 is decay-accelerating factor (CD55). J Virol. (1996) 70:5143–52.
170. Karnauchow TM, Tolson DL, Harrison BA, Altman E, Lublin DM, Dimock K. The HeLa cell receptor for enterovirus 70 is decay-accelerating factor (CD55). J Virol. (1996) 70:5143–52.
171. Karnauchow TM, Tolson DL, Harrison BA, Altman E, Lublin DM, Dimock K. The HeLa cell receptor for enterovirus 70 is decay-accelerating factor (CD55). J Virol. (1996) 70:5143–52.
172. Pinter C, Siccardi AG, Lopalco L, Longhi R, Clivio A. Mapping CD55 function. The structure of two pathogen-binding domains at 1.7 A. Proc Natl Acad Sci USA. (1995) 92:1127–36. doi: 10.1073/pnas.92.3.1127
173. Stoiber H, Pinter C, Siccardi AG, Clivio A, Dierich MP. Efficient destruction of human immunodeficiency virus in human serum by inhibiting the protective action of complement factor H and decay accelerating factor (DAF, CD55). J Exp. Med. (1996) 183:307–10. doi: 10.1084/jem.183.1.307
174. Bergelson JM, Chan M, Solomon KR, St John NF, Lin H, Finberg RW. Decay-accelerating factor (CD55), a glycosylphosphatidylinositol-anchored complement regulatory protein, is a receptor for several echoviruses. Proc Natl Acad Sci USA. (1994) 91:6245–8.
175. Williams P, Chaudhry Y, Goodfellow IG, Billington J, Powell R, Spiller OB, et al. Mapping CD55 function. The structure of two pathogen-binding domains at 1.7 A. J. Biol. Chem. (2003) 278:10691–6.
176. Saifuddin M, Parker CJ, Peeples ME, Gorny MK, Zolla-Pazner S, Ghassemi M, et al. Direct interaction of complement regulatory protein clusters with these terms. No use, distribution or reproduction is permitted which does not comply with these terms.
